跳至主要内容
临床试验/IRCT20180710040406N1
IRCT20180710040406N1招募中3 期

Assessment of the effect of Padzahr tablet on the turnover of bone formation in postmenopausal osteopenic women: A Randomized Double-Blind Placebo-Controlled Trial

iak company0 个研究点目标入组 44 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
45 years 至 65 years(—)
性别
Female

入选标准

  • Osteopenic postmenopausal women
  • Greater than 45 and under 65 years of age
  • Osteopenia, based on WHO definition: T Score between -2.5 and -1
  • No history of allergy and anaphylaxis

排除标准

  • Use of Tobacco products, Alcohol and narcotic products
  • History of choronic diseases, including Cancer, Cardiovascular diseases, Diabetes mellitus, Renal failure, Liver diseases, Systemic inflammatory diseases, Degenerative joint diseases, Rheumatologic disorders, Thalassemia, Primary hyperparathyroidism, Hyperthyroidism, Cushing's syndrome, Hypercalciuria, Hypogonadism
  • Gastrointestinal diseases, including Crohn's disease, Ulcerative colitis, Celiac, Choronic diarrhea, under treatment gastric or duodenal ulcer, history of gastrointestinal bleeding
  • History of drug consumption, affecting bone metabolism like Osteoporosis drugs , Diuretics, Thiazides, Anti convulsive drugs, Glucocorticoides and NSAIDES
  • Motor disability and skeletal disorders except Osteopenia
  • Untreated psychologic or neurologic diseases like Psychosis, Alzheimer and Parkinson Diseases
  • History of bone diseases
  • No tendency for randomization

研究者

发起方
iak company

相似试验